NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free MYGN Stock Alerts $21.40 -0.09 (-0.42%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$21.33▼$21.8050-Day Range$20.20▼$23.5952-Week Range$13.82▼$24.21Volume505,033 shsAverage Volume751,732 shsMarket Capitalization$1.92 billionP/E RatioN/ADividend YieldN/APrice Target$23.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Myriad Genetics alerts: Email Address Myriad Genetics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside8.3% Upside$23.17 Price TargetShort InterestBearish5.34% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.73Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.36) to ($0.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.78 out of 5 starsMedical Sector707th out of 939 stocksDiagnostic Substances Industry8th out of 13 stocks 1.2 Analyst's Opinion Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.17, Myriad Genetics has a forecasted upside of 8.3% from its current price of $21.40.Amount of Analyst CoverageMyriad Genetics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.34% of the outstanding shares of Myriad Genetics have been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Myriad Genetics has recently increased by 20.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMyriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Myriad Genetics is -0.60. Previous Next 2.6 News and Social Media Coverage News SentimentMyriad Genetics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Myriad Genetics this week, compared to 4 articles on an average week.Search Interest2 people have searched for MYGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Myriad Genetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.36) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTICBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! About Myriad Genetics Stock (NASDAQ:MYGN)Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Read More MYGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYGN Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comMyriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by AnalystsMarch 21, 2024 | globenewswire.comMyriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority DateMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 21, 2024 | finanznachrichten.deMyriad Genetics, Inc.: Myriad Genetics Announces Patent Granted for SneakPeek Snap DeviceMarch 20, 2024 | globenewswire.comMyriad Genetics Announces Patent Granted for SneakPeek® Snap DeviceMarch 16, 2024 | finance.yahoo.comMYGN Apr 2024 30.000 callMarch 16, 2024 | finance.yahoo.comMYGN Aug 2024 21.000 callMarch 16, 2024 | finance.yahoo.comMYGN May 2024 18.000 callMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 14, 2024 | msn.comCiti starts Catalyst at buy, cites rare disease drug portfolioMarch 1, 2024 | markets.businessinsider.comMyriad Genetics: Hold Rating Amidst Growth and Market UncertaintyFebruary 29, 2024 | finance.yahoo.comMyriad Genetics Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 28, 2024 | finance.yahoo.comMyriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comQ4 2023 Myriad Genetics Inc Earnings CallFebruary 28, 2024 | markets.businessinsider.comMyriad Genetics: Hold Rating Maintained Amid Balanced Performance and Cautious OutlookFebruary 27, 2024 | finance.yahoo.comMyriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023February 27, 2024 | seekingalpha.comMyriad Genetics, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | markets.businessinsider.comMyriad Genetics Inc. Q4 Earnings SummaryFebruary 27, 2024 | globenewswire.comMyriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue GuidanceFebruary 27, 2024 | globenewswire.comMyriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3February 26, 2024 | msn.comMyriad Genetics Q4 2023 Earnings PreviewFebruary 22, 2024 | benzinga.comMyriad Genetics Stock (NASDAQ:MYGN) Insider TradesFebruary 21, 2024 | finance.yahoo.comMyriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024February 21, 2024 | globenewswire.comMyriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024February 16, 2024 | morningstar.comMyriad Genetics Inc MYGNFebruary 16, 2024 | finanznachrichten.deMyriad Genetics, Inc.: Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's HealthFebruary 16, 2024 | finance.yahoo.comLarry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics IncSee More Headlines Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CUSIP62855J10 CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Stock Price Target$23.17 High Stock Price Target$31.00 Low Stock Price Target$14.00 Potential Upside/Downside+8.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,300,000.00 Net Margins-34.96% Pretax Margin-34.81% Return on Equity-8.03% Return on Assets-5.24% Debt Debt-to-Equity Ratio0.05 Current Ratio2.01 Quick Ratio1.87 Sales & Book Value Annual Sales$753.20 million Price / Sales2.55 Cash FlowN/A Price / Cash FlowN/A Book Value$9.53 per share Price / Book2.25Miscellaneous Outstanding Shares89,880,000Free Float88,078,000Market Cap$1.92 billion OptionableOptionable Beta1.96 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Paul J. Diaz (Age 62)CEO, President & Director Comp: $1.88MDr. Kevin Richard Haas Ph.D. (Age 38)Chief Technology Officer Comp: $580.36kMr. R. Bryan Riggsbee (Age 53)Strategic Advisor Comp: $845.15kMr. Mark S. Verratti (Age 56)Chief Commercial Officer Comp: $794.85kMs. Nicole Lambert (Age 50)Consultant Comp: $746.91kMr. Scott J. Leffler (Age 48)Chief Financial Officer Mr. Samraat S. Raha (Age 51)Chief Operating Officer Ms. Natalie Munk (Age 43)Principal Accounting Officer Dr. Dale Muzzey Ph.D. (Age 44)Chief Scientific Officer Mr. Matthew ScaloSenior Vice President of Investor RelationsMore ExecutivesKey CompetitorsCelldex TherapeuticsNASDAQ:CLDXMeridian BioscienceNASDAQ:VIVOIntellia TherapeuticsNASDAQ:NTLAHeskaNASDAQ:HSKAQuidelOrthoNASDAQ:QDELView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 757 shares on 3/22/2024Ownership: 0.006%Vanguard Group Inc.Bought 789,496 shares on 3/11/2024Ownership: 11.075%Wellington Management Group LLPBought 1,223,446 shares on 3/5/2024Ownership: 8.033%Fisher Asset Management LLCBought 15,313 shares on 3/5/2024Ownership: 0.176%Goldman Sachs Group Inc.Sold 103,032 shares on 3/1/2024Ownership: 1.324%View All Insider TransactionsView All Institutional Transactions MYGN Stock Analysis - Frequently Asked Questions Should I buy or sell Myriad Genetics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares. View MYGN analyst ratings or view top-rated stocks. What is Myriad Genetics' stock price target for 2024? 6 equities research analysts have issued 1 year price targets for Myriad Genetics' shares. Their MYGN share price targets range from $14.00 to $31.00. On average, they anticipate the company's stock price to reach $23.17 in the next year. This suggests a possible upside of 8.3% from the stock's current price. View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts. How have MYGN shares performed in 2024? Myriad Genetics' stock was trading at $19.14 on January 1st, 2024. Since then, MYGN shares have increased by 11.8% and is now trading at $21.40. View the best growth stocks for 2024 here. When is Myriad Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our MYGN earnings forecast. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) issued its earnings results on Tuesday, February, 27th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. The firm earned $196.60 million during the quarter, compared to analysts' expectations of $194.80 million. Myriad Genetics had a negative net margin of 34.96% and a negative trailing twelve-month return on equity of 8.03%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.20) earnings per share. What ETFs hold Myriad Genetics' stock? ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).SPDR S&P 600 Small Cap ETF (SLY). What guidance has Myriad Genetics issued on next quarter's earnings? Myriad Genetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 0.000-0.050 for the period, compared to the consensus estimate of -0.010. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of $819.3 million. What is Paul Diaz's approval rating as Myriad Genetics' CEO? 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS). Who are Myriad Genetics' major shareholders? Myriad Genetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.11%), Vanguard Group Inc. (11.08%), Wellington Management Group LLP (8.03%), Glenview Capital Management LLC (6.43%), Dimensional Fund Advisors LP (3.26%) and Artisan Partners Limited Partnership (2.96%). Insiders that own company stock include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Richard Bryan Riggsbee and S Louise Phanstiel. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Myriad Genetics have any subsidiaries? The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.Read More This page (NASDAQ:MYGN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsBill Ackman’s 2024 warningPorter & CompanyUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.